Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.48 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839577 | 0.81 | ALDH1A1 (0.39) | ALDH1A1HPGDNPC1RAB9ATP53 | |
| SCHEMBL28791217 | 0.80 | ALDH1A1 (0.56) | ALDH1A1HPGDNPC1RAB9ATP53 | |
| SCHEMBL12102616 | 0.79 | ALDH1A1 (0.55) | ALDH1A1HPGDNPC1RAB9ATP53 | |
| SCHEMBL838439 | 0.78 | PI4KA (0.43) | ALDH1A1HPGDNPC1RAB9ATP53 | |
| SCHEMBL1244897 | 0.78 | GPR119 (0.48) | ALDH1A1HPGDMAPTSMN1; SMN2LMNA | |
| SCHEMBL17802635 | 0.78 | CA9 (0.48) | — | |
| SCHEMBL23996438 | 0.76 | TP53 (0.52) | ALDH1A1HPGDNPC1RAB9ATP53 | |
| SCHEMBL23996447 | 0.76 | ALDH1A1 (0.52) | ALDH1A1HPGDNPC1RAB9ATP53 | |
| SCHEMBL23996454 | 0.76 | ALDH1A1 (0.52) | ALDH1A1HPGDNPC1RAB9ATP53 | |
| SCHEMBL21138500 | 0.76 | POLB (0.39) | ALDH1A1HPGDNPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756113-B1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM GMBH (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-8236809-B2 | Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation | VASOPHARM GMBH (DE) | 2012-08-07 | — | — | US | disclosed |
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | VASOPHARM GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1598354-A1 | Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation | Vasopharm Biotech GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | NQO1, CYBB, NADK | ALDH1A1 284/4885HPGD 14/4885NPC1 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.